Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625

BACKGROUND: Progressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostication in T1 non-progressors. We aimed to determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Boxerman, Jerrold L., Snyder, Bradley S., Barboriak, Daniel P., Schmainda, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909012/
https://www.ncbi.nlm.nih.gov/pubmed/36776298
http://dx.doi.org/10.3389/fonc.2023.1061502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909012/
https://www.ncbi.nlm.nih.gov/pubmed/36776298
http://dx.doi.org/10.3389/fonc.2023.1061502

Ejemplares similares